Bilici, A. Et Al. 2022. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. Cancer Investigation , vol.40, no.2 , 199-209.

Bilici, A., Uysal, M., Menekse, S., Akin, S., Yildiz, F., Turan, M., ... SEZGİN GÖKSU, S.(2022). Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. Cancer Investigation , vol.40, no.2, 199-209.

Bilici, Ahmet Et Al. "Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study," Cancer Investigation , vol.40, no.2, 199-209, 2022

Bilici, Ahmet Et Al. "Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study." Cancer Investigation , vol.40, no.2, pp.199-209, 2022

Bilici, A. Et Al. (2022) . "Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study." Cancer Investigation , vol.40, no.2, pp.199-209.

@article{article, author={Ahmet Bilici Et Al. }, title={Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study}, journal={Cancer Investigation}, year=2022, pages={199-209} }